Post-ESMO 2025!

Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.

With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.

Oct 26 •

Timothée Olivier

Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.

Access to HLA-restricted therapy differs according to patients ethnicity, and should ideally be overcome.

Oct 21 •

Timothée Olivier

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts